Get the Stockscreener App
15.95
6.18%
-1.05
After Hours:
15.88
-0.07
-0.44%
Wave Life Sciences Ltd stock is traded at $15.95, with a volume of 2.87M.
It is down -6.18% in the last 24 hours and up +128.18% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$17.00
Open:
$17.02
24h Volume:
2.87M
Relative Volume:
0.47
Market Cap:
$2.96B
Revenue:
$93.95M
Net Income/Loss:
$-129.87M
P/E Ratio:
-17.72
EPS:
-0.9
Net Cash Flow:
$-202.88M
1W Performance:
-10.24%
1M Performance:
+128.18%
6M Performance:
+136.30%
1Y Performance:
+19.79%
1-Day Range:
$15.52
$17.03
1-Week Range:
$15.52
$18.05
52-Week Range:
$5.28
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
15.95 | 3.16B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences (WVE) stock slides 6% — what traders are watching next - ts2.tech
Wave Life Sciences stock drops 6% as WVE traders size up next obesity data - ts2.tech
WAVE Life Sciences (NASDAQ:WVE) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
HC Wainwright maintains a buy rating on Wave Life Sciences Ltd. (WVE) - MSN
Wave Life Sciences stock tumbles 8.5% in first 2026 session as traders refocus on next WVE-007 readout - ts2.tech
WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 7.1%Here's What Happened - MarketBeat
Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target - Finviz
WAVE Life Sciences Positioned Within Nasdaq Index Biotech Innovation - Kalkine Media
Moody Aldrich Partners LLC Lowers Stock Holdings in WAVE Life Sciences Ltd. $WVE - MarketBeat
15 Best Stocks Under $25 to Buy Now - Insider Monkey
Wave Life Sciences’ (WVE) RNA Obesity Drug WVE-007 Shows Potential to Match GLP-1 Efficacy Without Muscle Loss - Yahoo Finance
H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE) - Finviz
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Voya Investment Management LLC Raises Stock Position in WAVE Life Sciences Ltd. $WVE - MarketBeat
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next - ts2.tech
WAVE Life Sciences (STU:1U5) EV-to-OCF : -14.67 (As of Dec. 25, 2025) - GuruFocus
What New Catalysts Are Rewriting the Narrative for Wave Life Sciences? - Yahoo Finance
Behavioral Patterns of WVE and Institutional Flows - Stock Traders Daily
Wave Life Sciences (WVE) Is Up 11.7% After Early WVE-007 Fat-Loss DataWhat's Changed - simplywall.st
Wave Life Sciences (WVE) Stock: December 24, 2025 News Roundup, Analyst Forecasts, and What Investors Are Watching Next - ts2.tech
Oppenheimer and Truist lift Wave Life Sciences Ltd. (WVE) price targets after positive trial - MSN
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
Oppenheimer and Truist Lift Wave Life Sciences Ltd. (WVE) Price Targets After Positive Trial - Insider Monkey
WAVE Life Sciences (NASDAQ:WVE) Stock Price Up 9.5%Still a Buy? - MarketBeat
7 Most Promising Gene Editing Stocks According to Analysts - Insider Monkey
Analysts Offer Predictions for WVE Q1 Earnings - MarketBeat
Wave Life Sciences (WVE) price target increased by 60.82% to 32.70 - MSN
Wave Life Sciences (WVE) Price Target Increased by 60.82% to 32.70 - Nasdaq
Dividend Watch: Is Wave Life Sciences Ltd. stock attractive for income investorsWeekly Profit Analysis & Weekly Watchlist for Hot Stocks - ulpravda.ru
Promising Biotech Stocks To Keep An Eye OnDecember 9th - MarketBeat
HC Wainwright & Co. Maintains Wave Life Sciences (WVE) Buy Recommendation - Nasdaq
WVE: HC Wainwright Raises Price Target to $30, Maintains Buy Rat - GuruFocus
Wave Life Sciences surges as obesity data reshapes long-term outlook - S&P Global
Market Catalysts: Is Wave Life Sciences Ltd. stock a smart buy before Fed meetingJuly 2025 PostEarnings & Stepwise Trade Execution Plans - Bölüm Sonu Canavarı
Will Wave Life Sciences Ltd. stock outperform tech sector in 2025Earnings Overview Report & Weekly Consistent Profit Watchlists - DonanımHaber
Is Wave Life Sciences Ltd. (1U5) stock positioned for digital growth era2025 Technical Overview & Consistent Profit Focused Trading Strategies - DonanımHaber
Will Wave Life Sciences Ltd. stock maintain growth storyPortfolio Update Report & Weekly Breakout Watchlists - Улправда
Is Wave Life Sciences Ltd. stock a smart buy before Fed meetingRate Cut & Low Volatility Stock Recommendations - DonanımHaber
Will Wave Life Sciences Ltd. stock keep outperforming rivalsJuly 2025 Analyst Calls & Stock Portfolio Risk Management - Улправда
Wave Life Sciences (WVE): Valuation Check After Positive WVE-007 Obesity Data And GlaxoSmithKline Backing - simplywall.st
Why Wave Life Sciences Ltd. stock is rated strong buy2025 Market Outlook & Safe Entry Point Identification - Улправда
Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data - ts2.tech
WAVE Life Sciences (NASDAQ:WVE) Shares Down 4.3%Here's Why - MarketBeat
CEO Moves: Is Wave Life Sciences Ltd stock supported by innovation pipeline2025 Market Trends & Step-by-Step Trade Execution Guides - moha.gov.vn
Wave Life Sciences (WVE) Is Down 19.2% After $350 Million Equity Raise On Obesity DataWhat's Changed - simplywall.st
Wave Life Sciences drops after trial data for GSK-partnered RNA-editing therapy - MSN
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - AOL.com
United StatesMintz Advises On Wave Life Sciences $402.5 Million Public Offering - Mondaq
Oppenheimer Maintains Wave Life Sciences (WVE) Outperform Recommendation - Nasdaq
Oppenheimer raises WAVE Life Sciences stock price target to $32 on WVE-007 data By Investing.com - Investing.com South Africa
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):